nav-left cat-right

Experimental Type 1 diabetes vaccine fails during second step of trial

The quest for a vaccine to stop Type 1 diabetes in its tracks has hit a roadblock.

An experimental drug failed in the second step of a three-phase trial on 145 American and Canadian patients who had just been diagnosed with the disease.

The vaccine is based on an enzyme that is targeted by a diabetes patient’s immune system.

Researchers hoped the vaccine would train the immune system to not attack the enzyme – a process that destroys the pancreas’ insulin-producing cells.

But according to a study published by the medical journal The Lancet on Monday, patients who got the vaccine experienced no difference in the progression of the disease.

The vaccine was aimed at Type 1 diabetes, which used to be known as juvenile diabetes and affects less than 10% of people with the disease.

Most sufferers have what’s known as adult-onset or Type 2 diabetes.

New research shows vitamin D may ward off those at risk for Type 2 from actually developing the disease.

A study released over the weekend revealed that patients with the high levels of the vitamin were 25% less likely than those with the lowest amounts to get diabetes.

Scientists theorize that vitamin D may help the body produce more insulin or increase the body’s sensitivity to insulin.